You are here

New Study of Abiraterone Suggests Using It Earlier in Prostate Cancer Treatment Cycle

J&J tested Zytiga with prednisone in a trial of 1,088 men with prostate cancer who hadn't received chemotherapy, comparing it with prednisone plus a placebo. The study began in 2009 and was due to finish in 2014, according to a government database of clinical trials.

But J&J said Thursday that an independent data monitoring committee recommended releasing results sooner than planned because an interim analysis showed "evidence of clinical benefit as well as continued evidence of favorable safety."

J&J said the interim analysis showed differences between Zytiga and placebo in two key goals for the trial: radiographic progression-free survival and overall survival.

Read the full article in the Wall Street Journal.

Recent Headlines

Almost 64% of Patients Showed Decreased Hemoglobin A1c Levels
Lifesaving Life Foam for Battlefield, Terrorist Attacks, Trauma
Cell Reprogramming Process May Benefit Patients Prone to Severe Hypoglycemia
Beagles Beat Out Advanced Technology
Over Half of Patients Had Reduced Pain Levels of 30% or More
Spina Bifida, Cleft Lip Among Defects Caused by Antiepilectics
Study Data Indicate Drug May Provide Complete Remission in PV
Teplizumab Slows Progression to Disease by at Least Two 2 Years
Over 25% of Study Patients Showed 6–12 Months Remission